Suppression of the c-erbB-2 gene product decreases transformation abilities but not the proliferation and secretion of proteases of SK-OV-3 ovarian cancer cells

British Journal of Cancer

Volumn 81, Issue 5, 1999, Pages 790-795

  Wiechen, K ^a   Karaaslan, S ^a   Turzynski, A ^a   Dietel, M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

c erbB 2 oncogene; Cell transformation; Ovarian cancer; Proteases; Single chain antibody

Indexed keywords

ANTIBODY; MATRIX METALLOPROTEINASE; ONCOPROTEIN; UROKINASE;

ARTICLE; CELL PROLIFERATION; CELL SURFACE; CELL TRANSFORMATION; CONTROLLED STUDY; EXPRESSION VECTOR; GENE REPRESSION; HUMAN; HUMAN CELL; ONCOGENE C ERB; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; RETROVIRUS;

ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; INTRACELLULAR FLUID; MATRIX METALLOPROTEINASES; OVARIAN NEOPLASMS; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 0032696701     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690765     Document Type: Article

References (23)

1. Beerli RR, Graus-Porta D, Woods-Cook K, Chen X, Yarden Y and Hynes NE (1995) Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. Mol Cell Biol 15: 6496-6505
2. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P, McKenzie S, Yin S and Bast RC Jr (1990) Overexpression of her-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50: 4087-4091
3. Chambers SK, Gertz RE, Ivins CM and Kacinski BM (1995) The significance of urokinase-type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer. Cancer 75: 1627-1633
4. Deshane J, Cabrera G, Grim J, Siegal GP, Pike J, Alvarez RD and Curiel DT (1995) Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody. Gynecol Oncol 59: 8-14
5. Deshane J, Grim J, Locchel S, Siegal GP, Alvarez RD and Curiel DT (1996) Intracellular antibody against erbB-2 mediates targeted tumor cell eradication by apoptosis. Cancer Gene Ther 3: 89-98
6. Deshane I, Siegal GP, Alvarez RD, Wang MH, Feng M, Cabrera G, Liu T, Kay M and Curiel DT (1995) Targeted tumor killing via an intracellular antibody against erbB-2. J Clin Invest 96: 2989-2989
7. Fukazawa H, Mizuno S and Uchara Y (1995) A microplate assay for quantitation of anchorage-independent growth of transformed cells. Anal Biochem 228: 83-90
8. Giani C, Casalini P, Pupa SM, De Vecchi R, Ardini E, Colnaghi MI, Giordano A and Menard S (1998) Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation. Oncogene 17: 425-432
9. Graus-Porta D, Beerli RR and Hynes NE (1995) Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Mol Cell Biol 15: 1182-1191
10. Graus-Porta D, Beerli RR, Daly JM and Hynes NE (1997) ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16: 1647-1655
11. Gum R, Wang SW, Lengyel E, Yu D, Hung M-C, Juarez J and Boyd D (1995) Up-regulation of urokinase-type plasminogen activator by expression by the HER2/neu proto-oncogene. Anticancer Res 15: 1167-1172
12. H F R2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci USA 84: 7159-7163
13. Kraus MH, Issing W, Miki T, Popescu NC and Aaronson SA (1989) Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci USA 86: 9193-9197
14. Meden H, Mars D, Rath W, Kron M, Faltahi-Meibodi A, Hinney B, Kuhn W and Schauer A (1994) Overexpression of the oncogene c-erbB2 in primary ovarian cancer: evaluation of the prognostic value in n Cox proportional hazards multiple regression. Int J Gynecol Pathol 13: 45-53
15. Noguchi M, Murakami M, Bennett W, Lupu R, Hui F, Harris CC and Gerwin BI. (1993) Biological consequences of overexpression of a transfected c-erbB-2 gene in immortalized human bronchial epithelial cells. Cancer Res 53: 2035-2043
16. Pear WS, Nolan GP, Scott ML and Baltimore D (1993) Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 90: 8392-8396
17. Plowman GD, Culouscu J-M, Whitney GS, Green JM, Carlton GW, Foy L, Neubauer MG and Shoyab M (1993) Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci USA 90: 1746-1750
18. Schmalfeldt B, Kuhn W, Reuning U, Pache L, Dettmar P, Schmitt M, Jänicke F, Höfler H and Graeff H (1995) Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. Cancer Res 55: 3958-3963
19. Tamakoshi K, Kikkawa F, Nawa A, Ishikawa H, Mizuno K, Tamakoshi A, Yamagata S, Suganuma N and Tomoda Y (1995) Characterization of extracellular matrix-degrading proteinase and its inhibitor in gynecologic cancer tissues with clinically different metastatic form. Cancer 76: 2565-2571
20. Tan M, Yao J and Yu D (1997) Overexpression of the c-erbH-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res 57: 1199-1205
21. Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, Saito T and Toyoshima K (1986) Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature (London) 319: 230-234
22. Yu DH and Hung M-C (1991) Expression of activated rat neu oncogene is sufficient to induce experimental metastasis in 3T3 cells. Oncogene 6: 1991-1996
23. Yu D, Wolf JK, Scanlon M, Price JE and Hung M-C (1993) Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res 53: 891-898